Literature DB >> 31905248

SIRPB1 promotes prostate cancer cell proliferation via Akt activation.

Qiong Song1,2,3, Siyuan Qin1,2, Laura E Pascal3, Chunlin Zou1,2, Wenchu Wang1,2, Haibo Tong1,2, Jian Zhang4, William J Catalona5, Rajiv Dhir6, Megan Morrell6, Goundappa K Balasubramani7, Yi Lu1,2,4, Zhou Wang3,6,8,9.   

Abstract

BACKGROUND: Signal regulatory protein β1 (SIRPB1) is a signal regulatory protein member of the immunoglobulin superfamily and is capable of modulating receptor tyrosine kinase-coupled signaling. Copy number variations at the SIRPB1 locus were previously reported to associate with prostate cancer aggressiveness in patients, however, the role of SIRPB1 in prostate carcinogenesis is unknown.
METHODS: Fluorescence in situ hybridization and laser-capture microdissection coupled with quantitative polymerase chain reaction was utilized to determine SIRPB1 gene amplification and messenger RNA expression in prostate cancer specimens. The effect of knockdown of SIRPB1 by RNA interference in PC3 prostate cancer cells on cell growth in colony formation assays and cell mobility in wound-healing, transwell assays, and cell cycle analysis was determined. Overexpression of SIPRB1 in C4-2 prostate cancer cells on cell migration, invasion, colony formation and cell cycle progression and tumor take rate in xenografts was also determined. Western blot assay of potential downstream SIRPB1 pathways was also performed.
RESULTS: SIRPB1 gene amplification was detected in up to 37.5% of prostate cancer specimens based on in silico analysis of several publicly available datasets. SIRPB1 gene amplification and overexpression were detected in prostate cancer specimens. The knockdown of SIRPB1 significantly suppressed cell growth in colony formation assays and cell mobility. SIRPB1 knockdown also induced cell cycle arrest during the G0 /G1 phase and enhancement of apoptosis. Conversely, overexpression of SIPRB1 in C4-2 prostate cancer cells significantly enhanced cell migration, invasion, colony formation, and cell cycle progression and increased C4-2 xenograft tumor take rate in nude mice. Finally, this study presented evidence for SIRPB1 regulation of Akt phosphorylation and showed that Akt inhibition could abolish SIRPB1 stimulation of prostate cancer cell proliferation.
CONCLUSIONS: These results suggest that SIRPB1 is a potential oncogene capable of activating Akt signaling to stimulate prostate cancer proliferation and could be a biomarker for patients at risk of developing aggressive prostate cancer.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  Akt signaling; C4-2; FISH; PC3; SIRPB1; prostate cancer; qPCR

Mesh:

Substances:

Year:  2020        PMID: 31905248      PMCID: PMC7421598          DOI: 10.1002/pros.23950

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  46 in total

1.  Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state.

Authors:  H Murillo; H Huang; L J Schmidt; D I Smith; D J Tindall
Journal:  Endocrinology       Date:  2001-11       Impact factor: 4.736

2.  Activation of protein-tyrosine phosphatase SH-PTP2 by a tyrosine-based activation motif of a novel brain molecule.

Authors:  H Ohnishi; M Kubota; A Ohtake; K Sato; S i Sano
Journal:  J Biol Chem       Date:  1996-10-11       Impact factor: 5.157

3.  Integrative genomic profiling of human prostate cancer.

Authors:  Barry S Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S Carver; Vivek K Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E Major; Manda Wilson; Nicholas D Socci; Alex E Lash; Adriana Heguy; James A Eastham; Howard I Scher; Victor E Reuter; Peter T Scardino; Chris Sander; Charles L Sawyers; William L Gerald
Journal:  Cancer Cell       Date:  2010-06-24       Impact factor: 31.743

4.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

Authors:  Christopher E Barbieri; Sylvan C Baca; Michael S Lawrence; Francesca Demichelis; Mirjam Blattner; Jean-Philippe Theurillat; Thomas A White; Petar Stojanov; Eliezer Van Allen; Nicolas Stransky; Elizabeth Nickerson; Sung-Suk Chae; Gunther Boysen; Daniel Auclair; Robert C Onofrio; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Karen Sheikh; Terry Vuong; Candace Guiducci; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Wasay M Hussain; Alex H Ramos; Wendy Winckler; Michelle C Redman; Kristin Ardlie; Ashutosh K Tewari; Juan Miguel Mosquera; Niels Rupp; Peter J Wild; Holger Moch; Colm Morrissey; Peter S Nelson; Philip W Kantoff; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nat Genet       Date:  2012-05-20       Impact factor: 38.330

5.  A new human prostate carcinoma cell line, 22Rv1.

Authors:  R M Sramkoski; T G Pretlow; J M Giaconia; T P Pretlow; S Schwartz; M S Sy; S R Marengo; J S Rhim; D Zhang; J W Jacobberger
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Jul-Aug       Impact factor: 2.416

6.  A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion.

Authors:  Y Fujioka; T Matozaki; T Noguchi; A Iwamatsu; T Yamao; N Takahashi; M Tsuda; T Takada; M Kasuga
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

7.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3).

Authors:  M E Kaighn; K S Narayan; Y Ohnuki; J F Lechner; L W Jones
Journal:  Invest Urol       Date:  1979-07

8.  [Chromosomal abnormalities in carcinoma and hyperplasia of the prostate].

Authors:  T Miyauchi; T Nagayama; K Maruyama
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1992-01

9.  Organoid cultures derived from patients with advanced prostate cancer.

Authors:  Dong Gao; Ian Vela; Andrea Sboner; Phillip J Iaquinta; Wouter R Karthaus; Anuradha Gopalan; Catherine Dowling; Jackline N Wanjala; Eva A Undvall; Vivek K Arora; John Wongvipat; Myriam Kossai; Sinan Ramazanoglu; Luendreo P Barboza; Wei Di; Zhen Cao; Qi Fan Zhang; Inna Sirota; Leili Ran; Theresa Y MacDonald; Himisha Beltran; Juan-Miguel Mosquera; Karim A Touijer; Peter T Scardino; Vincent P Laudone; Kristen R Curtis; Dana E Rathkopf; Michael J Morris; Daniel C Danila; Susan F Slovin; Stephen B Solomon; James A Eastham; Ping Chi; Brett Carver; Mark A Rubin; Howard I Scher; Hans Clevers; Charles L Sawyers; Yu Chen
Journal:  Cell       Date:  2014-09-04       Impact factor: 41.582

10.  The mutational landscape of lethal castration-resistant prostate cancer.

Authors:  Catherine S Grasso; Yi-Mi Wu; Dan R Robinson; Xuhong Cao; Saravana M Dhanasekaran; Amjad P Khan; Michael J Quist; Xiaojun Jing; Robert J Lonigro; J Chad Brenner; Irfan A Asangani; Bushra Ateeq; Sang Y Chun; Javed Siddiqui; Lee Sam; Matt Anstett; Rohit Mehra; John R Prensner; Nallasivam Palanisamy; Gregory A Ryslik; Fabio Vandin; Benjamin J Raphael; Lakshmi P Kunju; Daniel R Rhodes; Kenneth J Pienta; Arul M Chinnaiyan; Scott A Tomlins
Journal:  Nature       Date:  2012-07-12       Impact factor: 49.962

View more
  2 in total

1.  Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.

Authors:  Adrián Mosquera Orgueira; Roi Ferreiro Ferro; José Ángel Díaz Arias; Carlos Aliste Santos; Beatriz Antelo Rodríguez; Laura Bao Pérez; Natalia Alonso Vence; Ággeles Bendaña López; Aitor Abuin Blanco; Paula Melero Valentín; And Res Peleteiro Raindo; Miguel Cid López; Manuel Mateo Pérez Encinas; Marta Sonia González Pérez; Máximo Francisco Fraga Rodríguez; José Luis Bello López
Journal:  PLoS One       Date:  2021-05-04       Impact factor: 3.240

2.  A research of STEAP1 regulated gastric cancer cell proliferation, migration and invasion in vitro and in vivos.

Authors:  Zhe Zhang; Wen-Bin Hou; Chao Zhang; Yu-En Tan; Dong-Dong Zhang; Wen An; Si-Wei Pan; Wan-di Wu; Qing-Chuan Chen; Hui-Mian Xu
Journal:  J Cell Mol Med       Date:  2020-10-30       Impact factor: 5.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.